Acadia Pharmaceuticals (ACAD) reported Q2 adjusted earnings of $0.18 per share, significantly exceeding consensus estimates of $0.06, marking a 200% earnings surprise. Revenue climbed 16% year-over-year to $307.96 million, surpassing the expected $293.82 million. Notable growth came from Acadia’s DAYBUE and NUPLAZID products, along with a raised 2026 revenue guidance to between $1.24-$1.3 billion.
CVS Health (CVS) posted Q2 adjusted earnings of $2.58 per share, beating expectations by $0.71, and achieving revenue of $106.09 billion, outperforming the $100.17 billion forecast. The improved profitability in CVS’s insurance business was highlighted by a decrease in the medical benefit ratio to 87.4%. The company raised its full-year adjusted EPS guidance to between $7.90-$8.10.
Eli Lilly (LLY) recorded Q2 adjusted earnings of $8.38 per share, surpassing estimates of $6.01 by $2.37. Revenue soared 48% year-over-year to approximately $23 billion, fueled by strong sales of its diabetes and obesity products, including Mounjaro’s $9.94 billion and Zepbound’s $4.93 billion in sales. The full-year revenue guidance was increased to $85 billion-$87 billion.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
